Cellectis CLLS
NASDAQ CLLS
$3.24 -0.08 (-2.41%)
At close: Sep 4, 2026 · 4:00 PM EDT

Cellectis (CLLS) Income from Non-Controlling Interests (2015 - 2023)

Cellectis (CLLS) posted quarterly Income from Non-Controlling Interests of -$539.0 million for Q3 2025, up 17.33% year-over-year from -$459.4 million in Q3 2024, and down 182.67% quarter-over-quarter from $652.0 million in Q4 2024.

Analysis

Cellectis (CLLS) Income from Non-Controlling Interests (2015 - 2023) Analysis & Trends

Cellectis' Income from Non-Controlling Interests history runs 10 years deep, the most recent figure standing at -$539.0 million for Q3 2025.

  • In Q3 2025, Income from Non-Controlling Interests rose 17.33% year-over-year to -$539.0 million; the TTM figure through Sep 2025 stood at -$539.0 million (up 17.33% YoY), while the FY2023 annual figure was -$7.4 million, up 6.46% from the prior year.
  • Income from Non-Controlling Interests for Q3 2025 stood at -$539.0 million, down from $652.0 million in the prior quarter.
  • The five-year high for Income from Non-Controlling Interests was $652.0 million in Q4 2024, with the low at -$652.0 million in Q3 2024.
  • The 5-year median for Income from Non-Controlling Interests is -$2.8 million (2022), against an average of -$43.4 million.
  • The sharpest annual moves came in 2022 and 2023: Income from Non-Controlling Interests soared 129.92% in 2022, then tumbled 1075.1% in 2023.
  • Cellectis' Income from Non-Controlling Interests stood at -$3.1 million in 2021, then surged by 43.45% to -$1.7 million in 2022, then sank by 182.91% to -$4.9 million in 2023, then jumped by 13314.43% to $652.0 million in 2024, then slumped by 182.67% to -$539.0 million in 2025.
  • Business Quant data shows CLLS's Income from Non-Controlling Interests at -$539.0 million in Q3 2025, $652.0 million in Q4 2024, and -$652.0 million in Q3 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -
8 Royalty Pharma 28.45 Bn 27.61 Bn - 63.60 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -
10 Cellectis 321.90 Mn 155.05 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2023 -4.93 Mn
Mar 31, 2023 -2.45 Mn
Dec 31, 2022 -1.74 Mn
Sep 30, 2022 -2.80 Mn
Jun 30, 2022 -506,000.00
Mar 31, 2022 -2.85 Mn
Dec 31, 2021 -3.08 Mn
Sep 30, 2021 -2.66 Mn
Jun 30, 2021 -1.69 Mn
Mar 31, 2021 -3.48 Mn
Dec 31, 2020 6.12 Mn
Sep 30, 2020 -3.31 Mn
Jun 30, 2020 -3.59 Mn
Mar 31, 2020 -3.48 Mn
Dec 31, 2019 -3.95 Mn
Sep 30, 2019 -3.49 Mn
Jun 30, 2019 -3.19 Mn
Mar 31, 2019 -2.48 Mn
Dec 31, 2018 -2.99 Mn
Sep 30, 2018 -2.51 Mn